Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pipenzolate is a small molecule antimuscarinic (anticholinergic) agent primarily used to treat gastrointestinal motility disorders, such as irritable bowel syndrome, gastrointestinal spasms, flatulent dyspepsia, infantile colic, and functional gastrointestinal disorders. It acts as a smooth muscle relaxant by selectively inhibiting muscarinic acetylcholine receptors—particularly the M2 and M3 subtypes—thereby blocking the action of acetylcholine on smooth muscle in the gut. This results in reduced spasms and hypermotility of the gastrointestinal tract. Pipenzolate has also been studied for use in arrhythmia and peptic ulcer disease[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pipenzolate.